StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 13, 2026, 09:27 AM

Curis Reports Q1 Net Loss of $24.2M; Raises Going Concern Doubt

AI Summary

Curis Inc. reported a net loss of $24.2 million for Q1 2026, significantly wider than the $10.6 million loss in Q1 2025. The company's management expressed substantial doubt about its ability to continue as a going concern within the next year, citing recurring losses and the need for significant additional capital. Despite raising $18.9 million through financing activities in the quarter, including a January 2026 PIPE financing, the company's cash and cash equivalents stood at $15.0 million as of March 31, 2026.

Key Highlights

  • Net loss for Q1 2026 was $24.2 million, compared to $10.6 million in Q1 2025.
  • Cash and cash equivalents were $15.0 million as of March 31, 2026, up from $5.1 million at December 31, 2025.
  • The company reported an accumulated deficit of $1.27 billion as of March 31, 2026.
  • Net cash used in operating activities was $9.0 million for Q1 2026, up from $7.3 million in Q1 2025.
  • Proceeds from financing activities totaled $18.9 million in Q1 2026, including a January 2026 PIPE financing.
  • Revenues were $0 for Q1 2026, down from $2.4 million in Q1 2025 due to the sale of Erivedge royalties.
  • Stockholders approved an increase in authorized common stock from 68.3 million to 283.8 million shares.
  • A $12.8 million expense was recorded for the change in fair value of warrant liabilities in Q1 2026.